Drug Profile
Pumosetrag
Alternative Names: DDP 733; MKC 733Latest Information Update: 23 Jun 2015
Price :
$50
*
At a glance
- Originator Mitsubishi Chemical
- Developer Dynogen Pharmaceuticals; Edusa Pharmaceuticals; Mitsubishi Chemical
- Class Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Quinuclidines; Small molecules
- Mechanism of Action Serotonin 5-HT3 receptor partial agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Constipation; Dyspepsia; Gastro-oesophageal reflux; Irritable bowel syndrome; Reflux oesophagitis
Most Recent Events
- 12 Jul 2010 Phase-II clinical trials in Gastro-oesophageal reflux in USA (PO)
- 22 May 2008 Final safety and efficacy data from a phase IIa (IBS-c) trial in Irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008) ,
- 09 Nov 2007 Phase-II clinical trials in Irritable bowel syndrome in USA (PO)